Comparison of 2 medium cutoff dialyzers versus on‐line hemodiafiltration regarding depurative ability and albumin loss: An uncontrolled clinical research
Loading...
Official URL
Full text at PDC
Publication date
2022
Advisors (or tutors)
Editors
Journal Title
Journal ISSN
Volume Title
Publisher
Wiley
Citation
Martínez‐Miguel, Patricia, et al. «Comparison of 2 Medium Cutoff Dialyzers versus On‐line Hemodiafiltration Regarding Depurative Ability and Albumin Loss: An Uncontrolled Clinical Research». Artificial Organs, vol. 47, n.o 3, marzo de 2023, pp. 589-94. https://doi.org/10.1111/aor.14466.
Abstract
Abstract
Background
Hemodialysis (HD) techniques that best remove molecules in the middle to high molecular weight range are on-line hemodiafiltration (OL-HDF) and HD with medium cut-off (MCO) membranes. The aim of this study was to compare efficacy and safety of OL-HDF with FxCordiax HDF 800™, with HD with 2 MCO dialyzers: Theranova 500® and the new Elisio 21HX™ dialyzer.
Methods
Fourteen patients following treatment with OL-HDF using FxCordiax HDF 800™ were randomized to receive a consecutive 1-week HD treatment with Theranova 500® and Elisio 21HX™.The reduction rate (RR) of differently sized molecules was compared, as well as the variation rate in molecules smaller than 1000, detected by nuclear magnetic resonance based chemometrics (metabolomics). Albumin loss in dialysate was quantified.
Results
Lower RRs were found for molecules around 20 000 with Elisio 21HX™ compared to OL- HDF (RR prolactin 58.5% versus 66.7%, p = 0.034; RR Kappa light chain 63.1% versus 71.8%, p = 0.010). Albumin loss per session was higher with Theranova 500® than with OL-HDF and with Elisio 21HX™ (2249.9 ± 714.1 mg, 815.2 ± 474.0 mg, 442.9 ± 135.9 mg, p < 0.001, respectively). Metabolomic studies suggested, by semi-quantitative analysis, a greater depurative capacity of OL-HDF, followed by Elisio 21HX™, and then Theranova 500®.
Conclusions
In this study, HD with Theranova 500® has proven to be very similar in efficacy to OL-HDF, although with a significantly higher albumin loss. HD with Elisio 21HX™ resulted in lower removal of molecules around 20 000 compared to OL-HDF, with no significant difference compared to Theranova 500®, and with less albumin loss than Theranova 500®.
Description
ACKNOWLEDGMENTS
The Ethics Committee for Research involving medical products of the Hospital Universitario Príncipe de Asturias, at its meeting on 23 February 2021, and after evaluating the proposal by the sponsor regarding the specified study, considered issuing a FAVORABLE OPINION for the study to be carried out.
FUNDING INFORMATION
This work was partially financed by Nipro.